Vigilant Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vigilant Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$194K	Hold	550	–	–	0.01%	152
2023 Q1	$173K	Hold	550	–	–	0.01%	153
2022 Q4	$159K	Hold	550	–	–	0.01%	164
2022 Q3	$159K	Hold	550	–	–	0.01%	166
2022 Q2	$155K	Hold	550	–	–	0.01%	175
2022 Q1	$144K	Sell	550 -450	-45%	-$107K	0.01%	204
2021 Q4	$220K	Sell	1,000 -61	-6%	-$11.9K	0.02%	185
2021 Q3	$192K	Sell	1,061 -550	-34%	-$107K	0.02%	158
2021 Q2	$325K	Sell	1,611 -89	-5%	-$18.6K	0.03%	121
2021 Q1	$365K	Sell	1,700 -400	-19%	-$87.9K	0.03%	97
2020 Q4	$496K	Sell	2,100 -669	-24%	-$153K	0.05%	75
2020 Q3	$754K	Buy	2,769 +2,700	+3,913%	+$745K	0.08%	59
2020 Q2	$20K	Hold	69	–	–	﹤0.01%	251
2020 Q1	$16K	Buy	+69	New	+$15.8K	﹤0.01%	266
2019 Q3	–	Sell	-16	Closed	-$3K	–	427
2019 Q2	$3K	Buy	+16	New	+$2.8K	﹤0.01%	370
2016 Q4	–	Sell	-251	Closed	-$22K	–	297
2016 Q3	$22K	Hold	251	–	–	﹤0.01%	225
2016 Q2	$22K	Buy	+251	New	+$21.7K	﹤0.01%	219
2015 Q4	–	Sell	-200	Closed	-$21K	–	287
2015 Q3	$21K	Buy	+200	New	+$25.7K	﹤0.01%	207
2014 Q1	–	Sell	-200	Closed	-$15K	–	289
2013 Q4	$15K	Buy	+200	New	+$13.9K	﹤0.01%	211

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vigilant Capital Management's VRTX Position: Q2 2023 in Review

Vigilant Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2023 at 550 shares worth $194K. The position accounts for 0.01% of the portfolio, ranked #152.

Vigilant Capital Management first reported a position in VRTX in Q4 2013 and has held it in 19 quarters since. The position peaked at $754K in Q3 2020. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

Vigilant Capital Management held 550 shares of Vertex Pharmaceuticals worth $194K as of Q2 2023.
Vigilant Capital Management left its Vertex Pharmaceuticals share count unchanged in Q2 2023.
Vertex Pharmaceuticals made up 0.01% of Vigilant Capital Management's portfolio in Q2 2023, its #152 holding.
Vigilant Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 19 quarters since.
Vigilant Capital Management's Vertex Pharmaceuticals position peaked at $754K in Q3 2020.
1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.